Translational Neurodegeneration (Feb 2022)

LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease

  • Eunice Eun Seo Chang,
  • Philip Wing-Lok Ho,
  • Hui-Fang Liu,
  • Shirley Yin-Yu Pang,
  • Chi-Ting Leung,
  • Yasine Malki,
  • Zoe Yuen-Kiu Choi,
  • David Boyer Ramsden,
  • Shu-Leong Ho

DOI
https://doi.org/10.1186/s40035-022-00285-2
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are one of the most frequent genetic causes of both familial and sporadic Parkinson’s disease (PD). Mounting evidence has demonstrated pathological similarities between LRRK2-associated PD (LRRK2-PD) and sporadic PD, suggesting that LRRK2 is a potential disease modulator and a therapeutic target in PD. LRRK2 mutant knock-in (KI) mouse models display subtle alterations in pathological aspects that mirror early-stage PD, including increased susceptibility of nigrostriatal neurotransmission, development of motor and non-motor symptoms, mitochondrial and autophagy-lysosomal defects and synucleinopathies. This review provides a rationale for the use of LRRK2 KI mice to investigate the LRRK2-mediated pathogenesis of PD and implications from current findings from different LRRK2 KI mouse models, and ultimately discusses the therapeutic potentials against LRRK2-associated pathologies in PD.

Keywords